United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 15,000 Shares

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $7.43 on Friday, hitting $410.00. The company's stock had a trading volume of 498,743 shares, compared to its average volume of 464,869. The company has a market capitalization of $18.30 billion, a price-to-earnings ratio of 18.01, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56. The stock has a 50 day moving average of $359.20 and a 200-day moving average of $322.77. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the firm posted $5.38 EPS. The company's revenue was up 22.9% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. LSV Asset Management boosted its position in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after acquiring an additional 436,851 shares during the period. Swedbank AB acquired a new position in United Therapeutics during the 1st quarter valued at about $97,316,000. Canada Pension Plan Investment Board raised its position in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock worth $41,533,000 after buying an additional 153,700 shares in the last quarter. Assetmark Inc. lifted its stake in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock worth $150,492,000 after acquiring an additional 152,249 shares during the period. Finally, Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after acquiring an additional 92,240 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating on the stock in a research report on Thursday, August 1st. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Jefferies Financial Group upped their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Wells Fargo & Company raised their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 20th. Finally, TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.